Clinical trial
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's…
NCT00022581 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00022581 |
|---|---|
| Title | Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Thalidomide (NSC #66847, IND #48832) for Patients With Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma |
| Intervention type | Drug, Other |
| Interventions | thalidomide, laboratory biomarker analysis |
| Enrollment | 45 |
| Start date | Jul 1, 2001 |
| Primary completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: